New ulcerative colitis drug begins first human safety tests
Knowledge-focused
Not yet recruiting
This early-stage study tests whether a new drug called LYNC-101 is safe in 50 healthy adults aged 18-60. Participants receive either the drug or a placebo by IV, once or three times over several weeks. The goal is to check for side effects and how the drug moves through the body,…
Phase: PHASE1 • Sponsor: LyncBio Therapeutics Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:09 UTC